ImmuCell (ImmuCell) Float Percentage Of Total Shares Outstanding : 80.27% (As of Apr. 27, 2024)

View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ImmuCell's float shares is 6.22 Mil. ImmuCell's total shares outstanding is 7.75 Mil. ImmuCell's float percentage of total shares outstanding is 80.27%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ImmuCell's Insider Ownership is 19.84%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ImmuCell's Institutional Ownership is 5.43%.

ImmuCell Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ImmuCell's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	6.22	/	7.75
	=	80.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell (ImmuCell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

IUL:Germany

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

Executives

Bryan K. Gathagan	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen	director	C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin	other: See Explanation of Responses	C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin	other: See Explanation of Responses	310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb	director, officer: Vice President and CSO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams	officer: Vice Pres. of Mfg Operations	C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild	director, 10 percent owner	C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham	director, officer: President and CEO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde	other: Director of Sales and Marketin	56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce	director	56 EVERGREEN DRIVE, PORTLAND ME 04103